Tribute's Cambia Approved for Migraine

Nautilus Neurosciences announced that their Canadian promotional partner, Tribute Pharmaceuticals, a wholly owned subsidiary of Stellar Pharmaceuticals, was granted a Notice of Compliance (NOC) approval from Health Canada for Cambia (diclofenac potassium for oral solution) in the treatment of acute migraine with or without aura in adults. Cambia is expected to be launched in Canada during the second half of 2012. Cambia has been available to patients in the United States since May 2010.

Nautilus Neurosciences has exclusive marketing rights for Cambia in the United States and Canada, which they obtained from APR, a Swiss drug delivery and drug development company. Patents have been granted that protect the product in the United States through 2026.

"We congratulate our partners at Tribute Pharmaceuticals on the Health Canada approval and look forward to continuing to work with them on the Canadian launch of Cambia. We are excited that Cambia will be available as a treatment option for physicians and patients in Canada," said William Maichle, the CEO of Nautilus Neurosciences.

Mr. Maichle added, "[I] expect Nautilus Neurosciences to experience record growth in 2012 as Cambia continues to fill an important unmet need for patients suffering from the debilitating effects of migraine."

Date: March 22, 2012